Survival analysis of 36 patients with malignant mesothelioma

SHEN Wei; LIU Jiaqi; CHEN Junfei; YING Shibo; XIA Hailing; FENG Lingfang; JIN Mingying; JIANG Zhaoqiang.
Journal of Preventive Medicine ; (12): 66-69, 2022.
Artículo en Zh | WPRIM | ID: wpr-907065

Documentos relacionados

  1. [Survival analysis of 37 cases of malignant mesothelioma].
  2. A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma.
  3. What has changed in malignant mesothelioma between 1990 and 2019? A time- series analyses in Turkey.
  4. [Clinical analysis of combined immunotherapy in patients with malignant pleural mesothelioma].
  5. The value of cytology in distinguishing malignant mesothelioma: An institutional experience of 210 cases reclassified according to the International System for Reporting Serous Fluid Cytopathology (ISRSFC).
  6. Predicting survival for patients with mesothelioma: development of the PLACE prognostic model.
  7. Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.
  8. Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study.
  9. Clinical prognostic factors in pleural mesothelioma: best supportive care and anti-tumor treatments in a real-life setting.
  10. Epidemiology and outcome of peritoneal and pleural mesothelioma subtypes in Norway. A 20 year nation-wide study.